Dendreon (DNDN): How high will it go?

Now that Provenge, the prostate cancer drug from Dendreon (DNDN) got past FDA Phase 3 approval, what's next?

The stock jumped from under $30/share to $40/share from January 2010 to April 2010.

Then yesterday, the good news hit, and the stock closed at $50/share, and pre-market indicators already push it higher, yet.